11/16
06:05 am
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) was upgraded by analysts at Raymond James to a "moderate buy" rating.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) was upgraded by analysts at Raymond James to a "moderate buy" rating.
11/16
06:05 am
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) was downgraded by analysts at Leede Financial from a "strong-buy" rating to a "moderate buy" rating.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) was downgraded by analysts at Leede Financial from a "strong-buy" rating to a "moderate buy" rating.
11/14
08:15 am
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/14
08:00 am
oncy
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
Medium
Report
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
11/14
08:00 am
oncy
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
Medium
Report
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
11/13
02:12 am
oncy
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
07:00 am
oncy
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
Medium
Report
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
11/12
07:00 am
oncy
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
Medium
Report
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
11/11
07:05 am
oncy
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
Low
Report
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
11/11
07:00 am
oncy
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Low
Report
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
10/15
07:32 am
oncy
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
High
Report
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
10/4
09:00 am
oncy
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
High
Report
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
10/4
07:00 am
oncy
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
High
Report
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
9/24
09:15 am
oncy
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Medium
Report
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
9/20
11:08 am
oncy
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Low
Report
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
9/20
09:00 am
oncy
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Medium
Report
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
9/19
12:14 pm
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/19
12:08 pm
oncy
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
Low
Report
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
9/19
07:00 am
oncy
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Low
Report
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
9/6
08:00 am
oncy
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
Low
Report
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September